{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:24:36Z","timestamp":1786969476456,"version":"build-2736575974"},"reference-count":16,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["aao-hnsfjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngol.--head neck surg."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Rituximab causes B\u2010cell depletion and hypogammaglobulinemia, increasing risk for infections. This study aims to determine the incidence of chronic rhinosinusitis (CRS) in patients following rituximab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using chart review of patients prescribed rituximab between January 2019 and January 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Multisite study across Mayo Clinic Enterprise locations in Arizona, Florida, Minnesota, and Wisconsin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with documented rituximab use were included; those with pre\u2010existing CRS were excluded. Demographic and clinical data\u2014including timing and duration of rituximab therapy, CRS diagnosis, comorbidities (asthma, allergic rhinitis, GERD), and need for sinus surgery\u2014were collected. Descriptive statistics summarized patient characteristics. Group comparisons were performed using\n                      <jats:italic>t<\/jats:italic>\n                      \u2010tests, Mann\u2010Whitney\n                      <jats:italic>U<\/jats:italic>\n                      , and chi\u2010square tests. Analyses were conducted using SPSS v28.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 17,851 patients prescribed rituximab (median age 64.0 years, M:F ratio 1.1:1), 1105 (6.2%) developed CRS, with an annual incidence of 1.03% (1032 cases per 100,000 person\u2010years). The median duration of rituximab therapy for those diagnosed with CRS was 5.9 months (IQR, 0.5\u201042.6). Most CRS cases occurred after rituximab discontinuation (62.7%, n\u2009=\u2009693) compared to during active treatment (37.3%, n\u2009=\u2009412). The median delay between rituximab discontinuation and CRS diagnosis was 17.0 months (IQR, 4.3\u201041.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates an annual incidence of 1.03% for CRS diagnoses following rituximab. While prior studies report varying CRS incidences in the general population (0.25%\u20100.73%), our findings suggest increased risk among rituximab users. Most CRS diagnoses occurred after rituximab discontinuation, emphasizing the need for a comprehensive medication history review during CRS evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ohn.70390","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:25:50Z","timestamp":1786965950000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab"],"prefix":"10.1002","author":[{"given":"Kendra","family":"Walker","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery Mayo Clinic Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien A.","family":"Valencia\u2010Sanchez","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery Mayo Clinic Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prishae","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery Mayo Clinic Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Najmi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery Mayo Clinic Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-087X","authenticated-orcid":false,"given":"Angela M.","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery Mayo Clinic Florida Jacksonville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"5","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2022.02.016","article-title":"Mechanisms and pathogenesis of chronic rhinosinusitis","volume":"149","author":"Kato A","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1389201003379059","article-title":"Rituximab: the first monoclonal antibody approved for the treatment of lymphoma","volume":"1","author":"Grillo\u2010Lopez A","year":"2000","journal-title":"Curr Pharm Biotechnol"},{"key":"e_1_2_8_4_1","volume-title":"Riabni (rituximab\u2010arrx) [package insert]","year":"2020"},{"issue":"10","key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2010incidence and outcomes","volume":"107","author":"Makatsori M","year":"2014","journal-title":"QJM"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu J","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late\u2010onset neutropenia, and infections following rituximab","volume":"130","author":"Athni TS","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1945892418793522","article-title":"Understanding the propensity for chronic sinusitis in patients on immunosuppressive therapy","volume":"32","author":"Papagiannopoulos P","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"e_1_2_8_9_1","first-page":"S1","article-title":"Clinical practice guideline: adult sinusitis update","volume":"173","author":"Payne SC","year":"2025","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cea.14592","article-title":"Global incidence and prevalence of chronic rhinosinusitis: a systematic review","volume":"55","author":"Min HK","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoto.2016.2227","article-title":"Prevalence and incidence of diagnosed chronic rhinosinusitis in Alberta, Canada","volume":"142","author":"Xu Y","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long\u2010term safety of rituximab in rheumatoid arthritis: 9.5\u2010year follow\u2010up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Vollenhoven RF","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee CL","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan B","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10875-019-00636-1","article-title":"Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life?","volume":"39","author":"Bonagura VR","year":"2019","journal-title":"J Clin Immunol"},{"issue":"5","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jaci.2013.02.002","article-title":"Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis","volume":"131","author":"Tan BK","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler S","year":"2018","journal-title":"JAMA Netw Open"}],"container-title":["Otolaryngology\u2013Head and Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70390","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ohn.70390","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:25:53Z","timestamp":1786965953000},"score":1,"resource":{"primary":{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/10.1002\/ohn.70390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":16,"alternative-id":["10.1002\/ohn.70390"],"URL":"https:\/\/doi.org\/10.1002\/ohn.70390","archive":["Portico"],"relation":{},"ISSN":["0194-5998","1097-6817"],"issn-type":[{"value":"0194-5998","type":"print"},{"value":"1097-6817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"2025-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ohn.70390"}}